Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
Conclusion: Treatment with newly approved VEGFR-TKIs significantly increases the risk of developing proteinuria events in cancer patients, especially for patients treated with lenvatinib.
PMID: 32105149 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Zhang W, Feng LJ, Teng F, Li YH, Zhang X, Ran YG Tags: Expert Rev Clin Pharmacol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Proteinuria | Renal Cell Carcinoma | Study | Thyroid | Thyroid Cancer